Restless Legs Syndrome: What the Guidelines Actually Mean in Real Life
Restless Legs Syndrome (RLS) is common, disruptive, and usually manageable. The part that goes wrong is often not the diagnosis, but the long-term strategy. Before turning every uncomfortable evening into a "medication contest," modern guidelines tell us to start with the basics: iron, aggravating factors, and pattern recognition.
RLS is that undeniable urge to move your legs, usually accompanied by an uncomfortable, "creepy-crawly" sensation that gets worse in the evening when you're trying to rest.
The first step in treating RLS isn't always a pill. Doctors now focus on: 1. Iron Levels: Even if you aren't "anemic," your brain needs a specific amount of iron to process dopamine correctly. Boosting your iron can often fix the problem. 2. Checking Your Meds: Many common drugs—like Benadryl, some antidepressants, and even certain nausea meds—can make RLS much worse. 3. The Long Game: We used to use "dopamine drugs" (like Mirapex) first, but we learned that for many people, these drugs make the condition *worse* over time (this is called "augmentation"). Now, we start with safer, long-term strategies first.
Contemporary management of Restless Legs Syndrome (RLS/Willis-Ekbom Disease) has undergone a significant paradigm shift away from primary dopaminergic therapy toward iron optimization and alpha-2-delta ligands.
The Foundational Step: Iron Evaluation
Dopamine synthesis in the substantia nigra is iron-dependent. Guidelines now recommend a full iron panel (Ferritin, TIBC, Transferrin Saturation).- Ferritin Target: In RLS, a ferritin level <75 ng/mL (and sometimes up to 100 ng/mL) is considered low, even if the patient is not clinically anemic.
- Intervention: Oral iron repletion with Vitamin C, or IV iron (e.g., ferric carboxymaltose) if oral therapy fails or symptoms are severe.
- Intermittent RLS: Managed with behavioral strategies and as-needed medications (e.g., low-dose gabapentin or benzodiazepines).
- Chronic Persistent RLS: The first-line choice is now Alpha-2-delta ligands (Gabapentin enacarbil, Pregabalin) because they have a lower risk of augmentation compared to dopamine agonists.
- Differential: Clinicians must also rule out mimicking conditions like peripheral neuropathy, venous insufficiency, or positional discomfort.